02.10.2015 Views

studies

2015SupplementFULLTEXT

2015SupplementFULLTEXT

SHOW MORE
SHOW LESS
  • No tags were found...

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

956A AASLD ABSTRACTS HEPATOLOGY, October, 2015<br />

1529<br />

Elevated galectin-3 in cirrhotic heart increases TNFα<br />

and inhibits cardiac contractility in rats<br />

Hongqun Liu, Samuel S. Lee; university of calgary, Calgary, AB,<br />

Canada<br />

Background: Galectin-3 plays a key pathogenic role in heart<br />

failure. However, the role of galectin-3 in cirrhotic cardiomyopathy<br />

is unclear. The present study aimed to investigate the<br />

effects of galectin-3 on cardiomyopathy. Methods: Two sets of<br />

rats were used in this study, one to study structural changes and<br />

another for a functional study. There were 4 groups (n=6 in<br />

each group) in each set: bile duct ligation (BDL); BDL + galectin-3<br />

inhibitor (N-acetyllactosamine, LacNAc, 5 mg/kg); sham<br />

operation and sham + LacNAc. The rats were sacrificed 4<br />

weeks after surgery. Cardiac mRNA and protein contents were<br />

evaluated by RT-PCR and Western blots (Galectin-3, PKCα,<br />

fibronectin, collagen I and III). Heart and serum TNFα was<br />

measured by ELISA. Isolated cardiomyocyte contractility was<br />

measured by an IonOptix cell-shortening video system. Results:<br />

the galectin-3, fibronectin and collagen I/ III ratio were significantly<br />

increased in cirrhotic hearts. TNFα was significantly<br />

increased in BDL rats in both serum and heart compared with<br />

sham controls (744 ± 84 pg/ml vs 566 ± 61 pg/ml in serum,<br />

p< 0.01 and 310 ± 32 pg/mg protein vs 189 ± 21 pg/<br />

mg protein in heart, p

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!